Datapoint: Optum Rx to Add Two New Humira Copies to Formulary

UnitedHealth Group’s Optum Rx on June 23 said it will add two new Humira biosimilars, Boehringer Ingelheim’s Cyltezo and Sandoz’s Hyrimoz, to its standard formulary as of July 1. Optum Rx also includes Amgen’s Amjevita, which launched in January, on its formulary. The PBM — one of the “big three” and the first to cover any Humira biosimilar at parity — will also keep Humira in its formulary. Under the pharmacy benefit, Humira is a preferred product that requires utilization management, such as step therapy and/or prior authorization, for 93.5% of Optum Rx’s pharmacy lives.

SOURCE: MMIT Analytics, as of 6/26/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 12

Datapoint: Centene to Expand Cityblock Partnership to Florida

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 11

Datapoint: SCAN Wins Stars Challenge Against CMS

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 10

Datapoint: Blue Cross and Blue Shield of Kansas City to Exit MA Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today